Objective: to increase the use of low-dose sakubatroxvalsartan during routine treatment for patients with chronic heart failure who are in a state of aggravation, and to observe its actual efficacy. Methods: 120 patie...Objective: to increase the use of low-dose sakubatroxvalsartan during routine treatment for patients with chronic heart failure who are in a state of aggravation, and to observe its actual efficacy. Methods: 120 patients with chronic heart failure were selected and randomly divided into two groups. Both groups were given drugs according to their conditions. The observation group was changed to low-dose sakubatrivalsartan after stopping ACEI/ARB. Results: the results in table 2-5 showed that the values in the observation group were more satisfactory (P0.05). Conclusion: for patients with chronic heart failure exacerbation, switching to low-dose sakubatroxvalsartan 36/24 hours after ACEI/ARB withdrawal can better reduce heart rate, blood pressure, neuroendocrine hormones, improve cardiac function, and do not increase serious adverse reactions without affecting the clinical efficacy.展开更多
文摘Objective: to increase the use of low-dose sakubatroxvalsartan during routine treatment for patients with chronic heart failure who are in a state of aggravation, and to observe its actual efficacy. Methods: 120 patients with chronic heart failure were selected and randomly divided into two groups. Both groups were given drugs according to their conditions. The observation group was changed to low-dose sakubatrivalsartan after stopping ACEI/ARB. Results: the results in table 2-5 showed that the values in the observation group were more satisfactory (P0.05). Conclusion: for patients with chronic heart failure exacerbation, switching to low-dose sakubatroxvalsartan 36/24 hours after ACEI/ARB withdrawal can better reduce heart rate, blood pressure, neuroendocrine hormones, improve cardiac function, and do not increase serious adverse reactions without affecting the clinical efficacy.
